News and reporting on colorectal cancer.
The company expects to launch Signatera for clinical use in colorectal cancer next year and has started to recruit a sales team for the assay.
The liquid biopsy firm reported revenues of $60.8 million for the quarter, easily surpassing the consensus Wall Street estimate of $45.4 million.
A new study suggests that colorectal cancers increase their mutation rate to dodge treatment in a manner that mirrors microbial resistance mechanisms.
The company processed more than 200,000 tests during the quarter, an increase of 20 percent compared to the 167,000 tests it processed in Q3 of last year.
Researchers at MD Anderson Cancer Center found that somatic copy number alterations are more frequent in normal tissue surrounding tumor than in blood.
The company released new data showing that Cologuard 2.0 can detect colorectal cancer with higher sensitivity than the current version of the test.
The firm reported that test volumes for its Cologuard colorectal cancer screening test rose 89 percent year over year.
In PLOS this week: RAPGEF6 gene insertion linked to laryngeal paralysis in Miniature Bull Terriers, colorectal cancer risk among Zimbabweans, and more.
Although normal tissues with somatic mutations did not necessarily progress to cancer, researchers saw a jump in mutational burden in samples associated with cancer or cirrhosis.
New Horizon Health's test, ColoClear, is a stool-based DNA test specifically designed to detect colon cancer in individuals of Asian descent.
A genetic genealogy analysis helped secure the release of a California man from prison after getting his murder conviction overturned, the Guardian reports.
Technology Review discusses the concerns that come along with the ability to quickly synthesize viruses like SARS-CoV-2.
Researchers have uncovered large bacteriophages whose genomes include translational machinery, Live Science reports.
In PNAS this week: role for Myc in alternative splicing regulation in prostate cancer, variation in methylation in Arabidopsis, and more.